ALT
Altimmune, Inc.
ALT
Altimmune, Inc.
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolut